KMT2A and acute myeloid leukemia: Although RN2 (MLL-AF9/NrasG12V) and HOXA9–MEIS1-overexpressing AML cells showed high sensitivity to the combo treatment, bone marrow-derived macrophage proliferation was unaffected even at the highest doses (Fig. 2a).